Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-Lung06: trastuzumab deruxtecan + pembrolizumab versus platinum chemotherapy + pembrolizumab in first-line HER2-overexpressing non-squamous NSCLC
CTR20252204Phase 3Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab deruxtecan, pembrolizumab, sponsored by Daiichi Sankyo Co., Ltd.. Started Oct 2025; status: active.
02
Drugs
trastuzumab deruxtecanpembrolizumab
Beyond the preview
Go deeper on CTR20252204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252204.